Fluphenazine decanoate
Permitil, Prolixin (fluphenazine decanoate) is a small molecule pharmaceutical. Fluphenazine decanoate was first approved as Prolixin decanoate on 1982-01-01. It is used to treat psychotic disorders and schizophrenia in the USA. It is known to target 5-hydroxytryptamine receptor 6, D(1A) dopamine receptor, D(1B) dopamine receptor, D(2) dopamine receptor, histamine H1 receptor, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 2A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluphenazine decanoate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PROLIXIN DECANOATE | Bristol Myers Squibb | N-016727 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Fluphenazine enanthate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PROLIXIN ENANTHATE | Bristol Myers Squibb | N-016110 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Fluphenazine hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PROLIXIN | Bristol Myers Squibb | N-011751 DISCN | 1982-01-01 | 5 products |
PROLIXIN | Bristol Myers Squibb | N-012145 DISCN | 1982-01-01 | 1 products, RLD |
PERMITIL | Merck Sharp & Dohme | N-012034 DISCN | 1982-01-01 | 4 products |
PERMITIL | Merck Sharp & Dohme | N-012419 DISCN | 1982-01-01 | 1 products |
PERMITIL | Merck Sharp & Dohme | N-016008 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
fluphenazine decanoate | ANDA | 2023-04-04 |
fluphenazine hydrochloride | ANDA | 2023-05-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
psychotic disorders | — | D011618 | F20.81 |
schizophrenia | EFO_0000692 | D012559 | F20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
J2680 | Injection, fluphenazine decanoate, up to 25 mg |
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cervical intraepithelial neoplasia | D018290 | D06 | — | 2 | — | — | — | 2 | |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Uterine cervical dysplasia | D002578 | EFO_1000910 | N87 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Peanut hypersensitivity | D021183 | EFO_0007425 | 2 | — | — | — | — | 2 | |
Allergic rhinitis | D065631 | J30.9 | 1 | — | — | — | — | 1 | |
Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 3 | 3 |
Paresis | D010291 | HP_0001269 | — | — | — | — | 3 | 3 | |
Mobility limitation | D051346 | HP_0002355 | — | — | — | — | 3 | 3 | |
Hemorrhoids | D006484 | EFO_0009552 | K64 | — | — | — | — | 2 | 2 |
Postoperative pain | D010149 | G89.18 | — | — | — | — | 1 | 1 | |
Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | 1 | 1 | |
Neurologic gait disorders | D020233 | R26.1 | — | — | — | — | 1 | 1 | |
Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 1 | 1 |
Pharyngitis | D010612 | R07.0 | — | — | — | — | 1 | 1 | |
Rectal neoplasms | D012004 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | FLUPHENAZINE DECANOATE |
INN | fluphenazine |
Description | Fluphenazine is a member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the N-10 position. It has a role as a phenothiazine antipsychotic drug, a dopaminergic antagonist and an anticoronaviral agent. It is an organofluorine compound, a member of phenothiazines and a N-alkylpiperazine. It derives from a hydride of a 10H-phenothiazine. |
Classification | Small molecule |
Drug class | Typical antipsychotic |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1 |
Identifiers
PDB | — |
CAS-ID | 69-23-8 |
RxCUI | 4496 |
ChEMBL ID | CHEMBL1200854 |
ChEBI ID | — |
PubChem CID | 3372 |
DrugBank | DB00623 |
UNII ID | S79426A41Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR6
HTR6
DRD1
DRD1
DRD5
DRD5
DRD2
DRD2
HRH1
HRH1
HTR7
HTR7
HTR2A
HTR2A
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,889 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fluphenazine decanoate, Fluphenazine hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
30 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more